India Globalization Capital, Inc. IGC · Stock Open India Globalization Capital, Inc. in new tab
India Globalization Capital, Inc. Analysis (IGC)
Is India Globalization Capital, Inc. a good investment? India Globalization Capital, Inc. (IGC) is currently trading at 0.2790 USD.
Earnings Schedule: India Globalization Capital, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.08.
Investor FAQ
Does India Globalization Capital, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is India Globalization Capital, Inc.?
India Globalization Capital, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -0.06.
Company Profile
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| April 19, 2013 | 1:10 |
Community Discussion